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Available online 6 January 2016Depending on populations, 15 to 40% of patients have a familial form of Paget's disease of bone (PDB), which is
transmitted in an autosomal-dominant mode of inheritance with incomplete penetrance. To date, only SQSTM1
gene mutations have been linked to the disease. Several single nucleotide polymorphisms (SNPs) have been
associatedwith PDB in patient non-carriers of SQSTM1mutations, but they haveminor size effects. The current clin-
ical practice guidelines still recommend to measure total serum alkaline phosphatase (sALP) for PDB screening.
However, genetic or bone biomarkers alone may lack sensitivity to detect PDB. Thus, the objective of this study
was to develop a molecular test of PDB, combining genetic and bone biomarkers, in order to detect PDB, which is
frequently asymptomatic. We genotyped 35 SNPs previously associated with PDB in 305 patients, and 292 healthy
controls. In addition, serum levels of 14 bone biomarkers were assayed in 51 patients and 151 healthy controls.
Bivariate and multivariate logistic regression models with adjustment for age and sex were ﬁtted to search for a
combination of SNPs and/or bone biomarkers that could best detect PDB in patient non-carriers of SQSTM1
mutations. First, a combination of ﬁve genetic markers gave rise to the highest area under the ROC curve (AUC)
with 95% conﬁdence interval [95% CI] of 0.731 [0.688; 0.773], which allowed us to detect 81.5% of patients with
PDB. Second, a combination of two bone biomarkers had an AUC of 0.822 [0.726; 0.918], and was present in
81.5% of patients with PDB. Then, the combination of the ﬁve genetic markers and the two bone biomarkers
increased the AUC up to 0.892 [0.833; 0.951], and detected 88.5% of patients with PDB. These results suggested
that an algorithm integrating ﬁrst a screen for SQSTM1 gene mutations, followed by either a genetic markers
combination or a combined genetic and biochemical markers test in patients non-carrier of any SQSTM1mutation,
may detect the PDB phenotype better than biomarkers already available in the clinical practice.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Molecular test1. Introduction
Paget's disease of bone (PDB) is characterized by focal abnormal
bone remodeling, with increased bone resorption coupled with an
increased and disorganized new bone formation, resulting in abnormal
bone architecture and weakened bone strength. This disease affects up
to 3% of Caucasians over 55 years of age, which makes it the second
most frequent metabolic bone disorder after osteoporosis ([20]). In
most cases, patients with PDB are asymptomatic. However, 10 to 30%
of patients will develop symptoms and complications, such as boneU de Québec, 2705 boulevard
l.ca (L. Michou).
. This is an open access article underpain, bone deformities, fractures, deafness, or nerve root compression.
The development of an osteosarcoma is the most severe complication,
and occurs in less than 1% of patients with PDB ([28]).
PDBhas a strong genetic component. Depending on populations, 15 to
40% of patients have a familial formof the disease, which is transmitted in
an autosomal dominantmode of inheritancewith incomplete penetrance
([28]). Although genetic heterogeneity has been demonstrated in familial
forms of PDB, only the Sequestosome 1 (SQSTM1) gene at the 5q35 locus
has been linked to PDB, with nearly 30 disease-causingmutations identi-
ﬁed so far [19,26]. Overall, thesemutations in SQSTM1 gene are present in
about 35% of familial forms of PDB, and 7% of unrelated patients [14]. Two
genome wide association studies (GWAS) performed in PDB-affected
patients without SQSTM1 mutations identiﬁed seven loci associated
with PDB [2,4]. These associations were then replicated in otherthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Single nucleotide polymorphisms (SNPs) genotypes available for this study.
Loci Physical position SNP number Gene
1p13
110,201,580 Rs650985 GSTM4
110,352,477 Rs10494112b EPS8L3/CSF-1
110,361,682 Rs499345 EPS8L3/CSF-1
110,366,083 Rs484959 EPS8L3/CSF-1
3q24 18,160,060 Rs4688903 LOC339862
5q31 141,019,830 Rs11742646a RELL2
7q33 135,293,128 Rs4294134 NUP205
8q22
104,388,446 Rs35500845 CTHRC1
105,359,432 Rs2458413 TM7SF4
105,367,264 Rs62620995 TM7F4
8q24
119,950,668 Rs1485286b TNFRSFIIB
119,952,765 Rs11573871 TNFRSFIIB
119,953,158 Rs11573869 TNFRSFIIB
119,955,111 Rs6415470 TNFRSFIIB
119,964,283 Rs2073617 TNFRSFIIB
9p13 35,054,586 Rs565070 VCP
10p13
13,141,144 Rs3829923 OPTN
13,151,224 Rs2234968 OPTN
13,155,726 Rs1561570 OPTN
13,169,374 Rs825411 OPTN
13,184,045 Rs2095388 OPTN
13,276,751 Rs17152980 UCMA
10q11
54,074,757 Rs2241529 DKK1
54,076,271 Rs1569198 DKK1
54,086,453 Rs11001604 DKK1
10q23q24 100,322,658 Rs477950 HPSE2
14q32 93,103,309 Rs10498635a RIN3
15q24 74,336,633 Rs5742915 PML
17q11 41,829,296 Rs851062 SOST
18q21
59,751,331 Rs4941107 PIGN
59,979,135 Rs2980996 KIAA1468
60,082,093 Rs3018362 RPL17P14
18q22
60,021,761 Rs35211496a TNFRSFIIA
60,027,241 Rs1805034 TNFRSFIIA
60,060,735 Rs2957128 TNFRSFIIA
a SNPs departing from Hardy–Weinberg equilibrium in the control group.
b SNPs removed from further analyses because of complete linkage disequilibrium (D′=1)
with other SNPs studied.
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this population, some rare variants were also associated with PDB in pa-
tient non-carriers of SQSTM1 mutations [5,6]. Environmental factors
were reported to play an important role in PDB pathogenesis. Al-
though controversial in the literature, viral infection would contrib-
ute to the development of the disease, as osteoclasts expressing the
gene encoding for the measles virus nucleocapsid protein (MVNP) de-
velop a complete pagetic phenotype, both in cellular and animalmodels
[17].
Currently, a decline in theprevalence and severity of PDB is observed
in many countries previously known to have a high prevalence of PDB
[11,12]. This may increase the proportion of affected individuals who
remain asymptomatic, especially in familial forms. Given the high risk
of developing an osteosarcoma on pagetic bone, this disease is a formal
contraindication to the prescription of bone anabolic agents, such as
teriparatide. Indeed, the excessive stimulation of osteoblasts in individ-
uals affected but asymptomatic or predisposed to PDBmay increase the
risk of developing an osteosarcoma or more likely give rise to the
occurrence of a symptomatic PDB, representing serious adverse events
of these drugs. With the incoming introduction of anabolic agents
targeting natural inhibitors of osteoblasts indicated for osteoporosis
treatment, it will be crucial to exclude accurately the presence of PDB,
including in asymptomatic individuals. The current clinical practice
guidelines still recommend to measure total serum alkaline phospha-
tase (sALP) for PDB screening [29]. However, total sALP levels may be
within the normal range, especially in patients with monostotic or
metabolically inactive disease, and this should not exclude a diagnosis
of PDB ([25]). Since genetic or bonebiomarkers alonemay lack sensitivity
to predict the clinical diagnosis of PDB, we hypothesized that the combi-
nation of both kind ofmarkerswould be better. Thus, the objective of this
study was to develop amolecular test of PDB, including a combination of
genetic and bone biomarkers, in order to detect PDB.
2. Materials and methods
2.1. Individuals
The present study was approved by the CHU de Québec Ethics
Committee and all participants, affected or not, signed a consent
form before entering the study. A complete bone evaluation, including
total sALP measurement, skull and pelvis X-rays and a whole-body
bone scan,was performed for each patient. The criteria used to diagnose
PDBwere: 1) an increase in total sALP level and/or 2) a typical aspect of
PDB on the bone X-rays and/or 3) an abnormal whole-body bone scan,
as previously reported [18]. Patients with PDB originated from two
different countries: Canada (French–Canadian from a 120 km area
around Quebec City) and France (Angers, Paris, Saint-Etienne areas).
They had either a familial formof PDB, with only one affected per family
being included in this study, or they were unrelated affected individ-
uals. Clinical characteristics, including sex, family history of PDB, total
sALP levels (expressed as the number of times the midpoint of normal
range, in order to normalize results between patients), the age at PDB
diagnosis, the number of bone sites affected by PDB and the skeletal
extension calculated by the Reniers' index, were collected for each
patient [27]. General characteristics of patient cohorts and controls are
provided in Supplementary Table 1. Brieﬂy, in the French–Canadian
patients, the mean age at inclusion was 69.2 ± 9.6 years, 57.1%
were male, and 42.7% had amonostotic disease [19,24]. In the French
population, the mean age of PDB patients at inclusion was 62.7 ±
13.9 years, 50.0% were male, and 22.2% had a monostotic disease
[21]. An affected-only cohort of validation included PDB patients
from United States (New York city area). In this population, 44.3%
were male, and 54.3% had a monostotic disease [23]. Controls were
healthy individuals from the French–Canadian population living in an
area of 120 km around Quebec City without any personal or familial
history of PDB based on a questionnaire, and with normal total sALPlevels at inclusion. Bone scans were not done in this population.
The mean age of these healthy individuals at inclusion was 64.8 ±
10.9 years, and 28.8% were male. For each participant, DNA from
peripheral blood mononuclear cells (PBMCs) was extracted according
to standard procedures.2.2. SNP selection and genotyping
All study participants were previously screened for germinal
mutations in exons 7 and 8 of the SQSTM1 gene, and 47 patients
with PDB were carriers of a germinal SQSTM1 mutation: all patients
with a mutation were carriers of the SQSTM1/P392L germinal mutation,
except for two French individuals; one was carrier of SQSTM1/A390X
mutation, and the other of both SQSTM1/P392L and SQSTM1/A390Xmu-
tations. In addition, 15 participants were carriers of the SQSTM1/P392L
post-zygotic but not germinal mutation [15]. Thirty-ﬁve SNPs previous-
ly shown to be associated with PDB in the literature were genotyped
(Table 1) ([2,4–10,22]. Genotyping of SNPs relied on two different
methods: Sanger sequencing or Sequenom MassARRAY SNP Multiplex
Technology. The SNPs genotyped by the Sanger sequencing method
were ﬁrst ampliﬁed using a polymerase chain reaction (PCR). Ampliﬁca-
tion products were puriﬁed and sequencedwith Big Dye Deoxy Termina-
tor v 3.1 Cycle (Applied Biosystems) on an ABI 3730xl sequencer, and the
DNA sequences obtained were analyzed with Staden package version 1.6
([30]). For the SequenomMassARRAY SNPMultiplex Technology, the pu-
riﬁed DNA solution containingmultiplexed primer-based extension reac-
tion (iPLEX reaction) products was dispensed from the 384-wells
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nanodispenser. The mass of each SNP allele was detected on the
MassARRAY Compact MALDI-TOF (matrix-assisted laser desorption/
ionization – time of ﬂight) mass spectrometer. The results were ana-
lyzed with MassARRAY Typer 4 software. In order to verify the allele
calls, 3.7% of samples were randomly duplicated in the plate, and
yielded to a consistency of 100%. All genotyping procedures were per-
formed at the Plateforme de Séquençage et de Génotypage des
Génomes du Centre de Recherche du CHU de Québec. Each SNP was
genotyped in 287 French–Canadian patientswith PDB, 18 French patients
with PDB, and 292 healthy controls from the French–Canadian popula-
tion. Finally, ﬁve selected SNPs (see results section) were genotyped in
70 unrelated patients with PDB, from the New York city area population.
2.3. Bone biomarkers
Ten biomarkers associated with bone metabolism were assayed
in serum using commercial Roche Diagnostics immunoassay kits
(Hoffman's division LaRoche Ltée; Laval, Canada), according to
the manufacturer's protocol: procollagen type 1 amino-terminal
propeptide (P1NP), 25-OH vitamin D, interleukin-6 (IL-6), parathyroid
hormone (PTH), C-telopeptide, N-mid osteocalcin, calcium, albumin,
total ALP and high-sensitivity C-reactive protein (hsCRP). All these
immunoassays were performed using the Cobas E170 or the Cobas
c311 system at the Laboratoire de Biochimie de l'Hôpital St-Luc du
Centre Hospitalier de l'Université de Montréal. In addition, receptor
activator of nuclear factor κ-B ligand and osteoprotegerin (OPG) serum
levels were measured using commercially available ELISA kits from
Neobiolab (Cambridge, MA, USA), and serum levels of anti-measles
virus IgG were measured using the ELISA kit from IBL International
(Hamburg, Germany), according to themanufacturer's protocols. Finally,
sclerostin serum levels were measured using a homemade ELISA proto-
col. Brieﬂy, the plates were coated with 4 μg/mL of human sclerostin
monoclonal antibody (R&D, Minneapolis, USA) overnight at 4 °C. Then,
all wells were blocked for 2 hours with a 0.1 M Tris solution containing
8% of milk. After washing three times with a Tris-buffered saline solution
containing 0.05% of Tween20 (TTBS), samples and standards were incu-
bated overnight at 4 °C. The plate was washed again, and samples were
incubated 1 hour at 4 °C with 2 μg/mL of biotinylated antihuman
sclerostin immunoglobulin (R&D, Minneapolis, USA) for the detection
of the antigen. Then, samples were washed three times and incubated
for 1 hour at 4 °C with Streptavidin-HRP (R&D, Minneapolis, USA).
After a ﬁnal wash, the substrate (R&D, Minneapolis, USA) was added
and samples were incubated 20 minutes at room temperature. Finally,
the stop solution (R&D, Minneapolis, USA) was added, and the absor-
bance, determined as the optical density at 450 nm, was measured. The
intra-assay coefﬁcient of variation (CV) was 10.1%, and the inter-assay
CV was 7.3%. Each of these biomarkers was measured in serum samples
from 36 French–Canadian patients with PDB, 15 French patients with
PDB and 151 healthy controls from the French–Canadian population.
Serum sampleswere collected at the inclusion visit, aliquoted, and frozen
immediately at−80 until analyses. Serum samples were not available in
the New York city area population.
2.4. Statistical analyses
Hardy–Weinberg equilibrium was checked by a conformity χ2
test in controls. Linkage disequilibrium was calculated by the use of
Haploview software. Since there was one to ﬁve missing genotypes
in 10 SNPs, and one SNP (rs3829923) had 14 (2.35%) missing, these
genotypic data were imputed using the expectation–maximization
algorithm of multiple imputation procedure, which includes all
genetic markers. Genetic markers were dichotomized according to the
presence or absence of the at risk allele within the genotype. Patients
carrying a germinal or a post-zygotic SQSTM1 mutation were not
included into the statisticalmodels used to generate the different geneticand bone biomarkers combinations. To describe non-linear interactions
among all SNPs, we applied the multiple dimensionality reduction
(MDR) method, using 10-folds cross-validation. The subjects were
considered at high risk when they exceeded the threshold ratio (1.0).
The maximum cross-validation consistency and maximum testing
balanced accuracy were used for gene–gene interaction selection. Bivari-
ate analyses were performed to compare the frequencies of each SNP be-
tween cases and controls, using χ2 or Fisher's exact tests, with odds ratio
(OR) and 95% conﬁdence interval (95% CI) calculations. Then, bivariate
and multivariate logistic regression models with adjustment for age and
sex were ﬁtted to search for a unique SNP, or a combination of SNPs,
that could predict the PDB phenotype. The goodness of ﬁt for the last
models was veriﬁed using the Hosmer–Lemeshow test. A classiﬁcation
table was generated in order to establish a cut-off point for the predicted
probability of PDB based on estimated sensitivity and speciﬁcity.
Then, using the logistic regression estimates of each parameter, the
predicted probability of PDB was calculated for each individual, and
if this predicted probability was equal or greater than the established
cut-off point, the individual was considered as having a positive test.
In order to facilitate the results interpretation, this predicted proba-
bility was referred as a genetic score. The area under the receiving
operating characteristics (ROC) curve and 95% CI were estimated
for all of these models using DeLong et al.'s approach available in
SAS (DeLong, [13]). Intrinsic characteristics, including sensitivity,
speciﬁcity, positive and negative likelihood ratios, as well as extrin-
sic characteristics, including positive and negative predicting values
(PPV and NPV) with 95% CI were also calculated. Then, analyses were
performed with 243 patients with PDB, of whom 231 were French–
Canadians and 12 were French, and 292 healthy controls.
Serum calciumwas corrected for albumin, using the standard formula
(corrected calcium (mmol/L) = total calcium (mmol/L) + 0.02 × [40−
albumin (g/L)]), and a scale change of this variable in μmol/Lwas applied.
Bivariate analyses were performed to compare the mean of each bone
biomarker between cases and controls. Student t or Wilcoxon tests
were used, depending on the variable distribution. Then, logistic regres-
sion models with adjustment for age and sex were ﬁtted to search for a
combination of biomarkers that could detect the PDB phenotype. The
area under the ROC curve (AUC) and 95% CI were also calculated for
each bone biomarker separately, and then in combination. Intrinsic and
extrinsic characteristics were also calculated for the bone biomarkers
combinations. In order to establish a cut-off point for continuous vari-
ables, a classiﬁcation table was generated. Then, the estimates of each pa-
rameter given by the logistic regression analysis were used to calculate
the predicted probability of PDB for each individual. In this model, the
predicted probability was referred as a biochemical score. Analyses
were then performed with 27 PDB-affected patients (16 French–Cana-
dians and 11 French), and 151 healthy controls. We further combined
the genetic and biochemical markers in the same logistic model to test
if it increased the diagnostic detection. The predicted probability of a pos-
itive score for PDB detection for this model was calculated as previously
described, andwas referred as a combined score in this study. These anal-
yses included 26 patients with PDB (16 French–Canadians and 10
French), and 151 healthy controls. For the genotype–phenotype associa-
tions, we compared PDB patients with a genetic score equal or greater
than the established cut-off point to PDB patients with a genetic score in-
ferior than this cut-off point, for the following items: familial history of
PDB, age at diagnosis, total sALP levels, number of affected bones, and
Reniers' index. Analyses relied on Student t test for continuous variables,
and χ2 of Fisher's exact tests when appropriate for nominal values.
Genotype–phenotype association analyses included patients with PDB
from the three populations available to this study. Statistical analyses
were performed using SAS 9.4, MDR v 3.0.2, and IBM SPSS Statistics
21. Intrinsic and extrinsic characteristics for each molecular test were
calculated using SAS and the online platform https://www.medcalc.
net/tests/diagnostic_test.php. For all analyses, a p value of b0.05 was
considered statistically signiﬁcant.
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Three SNPs departing from Hardy–Weinberg equilibrium
(rs11742646, rs10498635 and rs35211496) were excluded from the
analyses. In addition two SNPs were in complete linkage disequilibrium
with other SNPs studied, rs10494112 with rs499345 as well as rs484959,
and rs1485286with rs2073617. Then, a total of 30 SNPswere included in
the analyses (Table 1). We searched for gene–gene interactions between
SNPs using a MDR approach. However, no combination was found to be
signiﬁcantly associated with PDB (data not shown).
3.1. Combination of genetic markers
In bivariate analyses, nine of the 30 SNPs were associated with PDB in
our population (Supplementary Table 2). All these SNPs had an AUC
varying between 0.500 and 0.585, suggesting that individually, these
SNPs are not good markers to detect PDB in patient non-carriers of
SQSTM1 mutations. Logistic regression analysis, adjusted for age
and sex, showed that a combination of six genetic markers, consisting in
rs499345 (EPS8L3/CSF-1), rs5742915 (PML), rs2458413 (TM7SF4),
rs3018362 (RPL17P14), rs2234968 (OPTN) and rs62620995 (TM7SF4),
yielded to most signiﬁcant results. The AUC for this combinationFig. 1. Area under the receiver operating characteristic (ROC) curve (AUC) calculations for the
marker included in the combinations and AUC graphs is presented for each combination: A)
combination including the genetic and biochemical markers.was 0.767 [0.727; 0.807] (p b 0.0001), but the at risk genetic marker
rs62620995 was a rare variant, present in a very small number of
individuals (3.9%), which may limit the use of this marker in other
populations. While removing this SNP from the combination, and
adjusting the model for sex only, we noticed that the AUC for the
combination of the ﬁve remaining genetic markers was still at
0.731 [0.688; 0.773] (p b 0.0001) (Fig. 1A). The logistic regression
estimates of each parameter in this model were as follows:
Odds of disease = Exp [−2.8535 + (sex*1.2590) +
(rs499345*0.5316) + (rs5742915*0.6064) + (rs2458413*0.7487)
+ (rs3018362*0.7037) + (rs2234968*0.5751)].
Predicted probability (genetic score) = Odds of disease/(1 + Odds
of disease)
where sex = 1 for a man, and 0 for a woman; and genetic marker
values = 1 when the at risk allele was present in the genotype, and 0
when the at risk allele was absent in the genotype (see Supplementary
Table 1 for detailed genotype information).
Using a cut-off point of 0.33 for the genetic score, this ﬁve genetic
marker combination, adjusted for sex, had a sensitivity of 81.5%, a
speciﬁcity of 51.0%, and positive and negative likelihood ratios of 1.7
and 0.4, respectively. PPV and NPV were at 58.1% and 76.8%, respectively
(Table 2). The cut-off was exceeded in 198 (81.5%) patients withmost signiﬁcant biomarker combinations developed in this study. The description of each
the genetic markers combination; B) the biochemical markers combination; and C) the
Table 2
Intrinsic and extrinsic characteristics for the main molecular tests developed in this study.
P1NPb
n= 177
Total alkaline
phosphatasesc
n= 178
Germinal
SQSTM1
mutations
n= 597
Five genetic
markers
combinationd
n= 535
Genetic
algorithme
n= 597
Two bone
biomarkers
combinationf
n= 177
Genetic and biochemical
markers combinationg
n= 176
Genetic and
biochemical
algorithma
n= 199
True positive, n 19 21 47 198 255 22 23 46
True negative, n 102 77 292 149 149 73 81 81
False positive, n 48 74 0 143 143 77 69 69
False negative, n 8 6 258 45 50 5 3 3
Sensitivity [95% CI],
%
70.37
[49.82;
86.25]
77.78 [57.74;
91.38]
15.41
[11.55;
19.96]
81.48 [76.02;
86.16]
83.61
[78.96;
87.58] 81.48 [61.92; 93.70]
88.46
[69.85; 97.55] 93.88 [83.13; 98.72]
Speciﬁcity [95% CI],
%
68.00
[59.90;
75.37]
50.99 [42.74;
59.21]
100.00
[98.74;
100.00]
51.03 [45.14;
56.90]
51.03
[45.14;
56.90] 48.67 [40.43; 56.95] 54.00 [45.68; 62.16] 54.00 [45.68; 62.16]
Positive predictive
value [95% CI], %
28.36
[18.01;
40.69]
22.11 [14.23;
31.78]
100.00
[92.45;
100.00]
58.06 [52.63;
63.36]
64.07
[59.14;
68.79] 22.22 [14.48; 31.69] 25.00 [16.55; 35.11] 40.00 [30.98; 49.55]
Negative predictive
value [95% CI], %
92.73
[86.17;
96.81]
92.77 [84.93;
97.30]
53.09
[48.82;
57.33]
76.80 [70.22;
82.55]
74.87
[68.25;
80.74] 93.59 [85.67; 97.89] 96.43 [89.92; 99.26] 96.43 [89.92; 99.26]
Positive likelihood
ratio [95% CI]
2.20 [1.57;
3.08]
1.59 [1.22;
2.06] – 1.66 [1.46; 1.90]
1.71 [1.50;
1.94] 1.59 [1.25; 2.01] 1.92 [1.54; 2.40] 2.04 [1.69; 2.46]
Negative likelihood
ratio [95% CI]
0.44 [0.24;
0.79]
0.44 [0.21;
0.90]
0.85 [0.81;
0.89] 0.36 [0.27; 0.48]
0.32 [0.24;
0.42] 0.38 [0.17; 0.85] 0.21 [0.07; 0.63] 0.11 [0.04; 0.34]
95% CI = 95% conﬁdence interval.
a The genetic and biochemical algorithm consists in germinal SQSTM1 mutations test followed by the combination integrating both genetic and biochemical markers.
b Calculated using a cut-off point of 46.89 ng/mL.
c Calculated using a cut-off point of 68.90 U/L.
d The probability level for a positive genetic score for Paget's disease of bone was ≥0.33.
e The genetic algorithm consists in germinal SQSTM1mutations test followed by the genetic combination.
f The probability level for a positive biochemical score for Paget's disease of bone was ≥0.07.
g The probability level for a positive combined score for Paget's disease of bone was ≥0.05.
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(p b 0.0001, OR = 4.6 [3.1; 6.8]). Among these patients, 29 different
genotype combinations resulting in a genetic score ≥ 0.33were observed,
including 24 combinations in men and 5 in women, respectively
(Supplementary Table 3).3.2. Frequency of individuals with a genetic score ≥ 0.33 in an independent
cohort
We estimated the frequency of individuals with a genetic score ≥ 0.33
in an independent cohort of unrelated patients with PDB from United
States (New York city area). All individuals who are carrier of a
SQSTM1 mutation were removed from this analysis. Forty-nine out
of 63 patients with PDB (77.8%) had a genetic score greater than
0.33, and were then correctly classiﬁed as PDB-affected individuals.
These patients had various ethnic ancestries: 15 were Italian Americans,
19 were Jewish (originating from Hungary, Belarus or Ukraine), and the
others originating from different European countries or from Africa or
the Caribbean. These results suggested that the genetic combinationTable 3
Comparisons of main clinical characteristics between patients with Paget's disease of bone (PDB
not carrier of any SQSTM1 gene mutation.a*
Categories of patients with PDB
PDB patients with a genetic score ≥ 0.33
(n= 247)
PDB pat
(n= 59
Positive family history of PDB 47 (19.34) 11 (18.6
Age at diagnosis (years), mean ± SD 61.70 ± 11.94 64.89 ±
Total sALP levelsa 3.25 ± 3.35 2.03 ±
Number of affected bones, mean ± SD 2.57 ± 2.22 2.15 ±
Reniers' index (%), mean ± SD 10.57 ± 9.01 8.58 ±
a For total sALP levels, values are expressed as the number of times the midpoint of normalwas not restricted to the French–Canadian population, and can be found
with a similar frequency in a multiethnic population.
3.3. Genotype–phenotype associations
PDB patients with a genetic score ≥ 0.33 had signiﬁcant higher sALP
levels than PDB patients with a genetic score b 0.33 (3.25± 3.35 versus
2.03± 1.42, p b 0.0001) (Table 3). We did not ﬁnd any other genotype–
phenotype association. These results suggest that PDB patients with a
genetic score ≥ 0.33 may have a more active disease, based on the
sALP levels measurement.
3.4. Combination of bone biomarkers
The bivariate analyses showed that PDB patients had a statistically
signiﬁcant higher serum levels of P1NP, C-telopeptide, calcium, total
ALP and OPG, and a lower serum level of sclerostin compared to healthy
controls (Supplementary Table 4). The bone biomarkers with the
greatest AUC were calcium, total ALP, and P1NP: 0.747, 0.739 and
0.721, respectively. P1NP and total ALPwere considered as gold standards) with a genetic score ≥ 0.33 versus patients with PDBwith a genetic score b 0.33; all were
Comparison of patients with a genetic score ≥ 0.33
to patients with PDB with a genetic score b 0.33
ients with a genetic score b 0.33
)
p Value
4) 0.903
11.69 0.106
1.42 b0.0001
2.28 0.204
8.15 0.123
range; SD = standard deviation; sALP = serum alkaline phosphatase.
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biomarker alone had a sensitivity of 70.4%, a speciﬁcity of 68.0%, and a
positive and negative likelihood ratios of 2.2 and 0.4. PPV and NPV were
at 28.4% and 92.7%, respectively. Regarding the total ALP, with the use of
the cut-off point 68.90 U/L, this biomarker had a sensitivity of 77.8%, a
speciﬁcity of 51.0%, a positive and a negative likelihood ratios of 1.6 and
0.4, and a PPV andNPV of 22.1% and 92.8%, respectively (Table 2). Logistic
regression analysis, adjusted for age and sex, showed that a combination
of ﬁve bone biomarkers, including calcium, P1NP, N-mid osteocalcin, OPG
and sclerostin, had the highest AUC: 0.887 [0.821; 0.953] (p b 0.0001).
However, since N-mid osteocalcin had a negative coefﬁcient estimate
and agewas not signiﬁcantly associated to PDB in themultivariate logistic
regression model, we decided to remove these parameters from the
combination. Also, we noticed that the AUC for a two bone markers
combination, consisting in calcium and P1NP, most likely to be used in
the clinical practice, had similar results: AUC = 0.822 [0.726; 0.918],
p b 0.0001 (Fig. 1B). The logistic regression estimates of each parameter
in this model were as follows:
Odds of disease = Exp [−27.6491 + (sex*0.6241) +
(Calcium*0.0106) + (P1NP*0.0184)].
Predicted probability (biochemical score) = Odds of disease/
(1 + Odds of disease)
where sex = 1 for a man, and 0 for a woman; calcium and P1NP
values were in μmol/L and ng/mL respectively.
Using a cut-off point of 0.07 for the biochemical score, this two bone
biomarker combination, adjusted for sex, had a sensitivity of 81.5%, a
speciﬁcity of 48.7%, and positive and negative likelihood ratios of 1.6
and 0.4, respectively. PPV andNPVwere at 22.2% and 93.6%, respectively
(Table 2). The cut-off was exceeded in 22 (81.5%) patients with PDB
(including 9 French patients), and 77 (51.3%) healthy controls (p =
0.004, OR = 4.2 [1.5; 11.6]).
3.5. Combination of genetic and biochemical markers
We then integrated both genetic and biochemical markers into the
same logistic model, adjusted for age and sex. The combination with
the highest AUC to predict the PDB phenotype consisted in the ﬁve at
risk genetic markers cited above, and calcium, P1NP, osteocalcin, OPG
and sclerostin (AUC = 0.928 [0.885; 0.972], p b 0.0001). Again the
combination integrating calcium and P1NP, adjusted for sex only, and
more likely to be widely used in the clinical practice, had similar results
with an AUC of 0.892 [0.833; 0.951] (p b 0.0001) (Fig. 1C). The logistic
regression estimates of each parameter in this model were as follows:
Odds of disease = Exp [−30.9036 + (sex*0.5957) +
(rs499345*0.4824) + (rs5742915*1.3519) + (rs2458413*0.3675)
+ (rs3018362*1.6467) + (rs2234968*0.4279) +
(calcium*0.0106) + (P1NP*0.0202)].
Predicted probability (combined score) = Odds of disease/
(1 + Odds of disease).
where sex = 1 for a man, and 0 for a woman; genetic marker
values = 1 when the at risk allele was present in the genotype, and 0
when the at risk allele was absent in the genotype; calcium and P1NP
values were in μmol/L and ng/mL respectively.
Using a cut-off point of 0.05 for the combined score, this combina-
tion, adjusted for sex, had a sensitivity of 88.5%, a speciﬁcity of 54.0%,
a positive likelihood ratio of 1.9, a negative likelihood ratio of 0.2, and
a PPV and NPV of 25.0% and 96.4%, respectively. The cut-off was
exceeded in 23 (88.5%) patients with PDB (including 10 French
patients), and 69 (46.0%) healthy individuals (p b 0.0001, OR = 9.0
[2.6; 31.3]).
3.6. Development of a molecular test, integrating SQSTM1 mutations
screening followed by both genetic and bone biomarkers combinations
In our French–Canadian and French populations, 62 (20.3%) of
patients with PDB were carriers of a SQSTM1 mutation, and none ofhealthy controls were carrier of any SQSTM1 mutation. Among them,
15 were carriers of a post-zygotic SQSTM1/P392L mutation. The best
scenario for the development of a molecular test would have been to
screen for both germinal and post-zygotic SQSTM1mutation to identify
the highest number of predisposed individuals. However, since the
detection of post-zygotic mutations may be tedious, we decided to
restrain the SQSTM1 screening to germinal mutations in the molecular
test in order to facilitate its development. Then, post-zygotic individuals
were considered as negative for the SQSTM1 screening in the ﬁrst step of
the algorithm. But afterwards, 10 out of 15 (66.7%) of the PDB patients
carrier of this post-zygotic mutation were found to have a genetic
score ≥ 0.33, suggesting that the majority of them should be detected
by the second step of the molecular test. In this sample, the screening
for germinal SQSTM1mutations had a sensitivity of 15.4%, a speciﬁcity
of 100%, a PPV of 100%, a NPV of 53.1%, and a negative likelihood ratio
of 0.9 (Table 2). Depending on the nature of the samples available,
two distinct molecular tests to detect PDB could be proposed. First, if
only DNA samples are available, a pure genetic molecular test, relying
on a two steps algorithm could be used: ﬁrst a screen in the SQSTM1
gene should be performed to search for disease-causing germinal
mutations, and if negative, the genetic score based on the combination
of the ﬁve SNPs developed in this study should be calculated (Fig. 2A).
In our populations, this pure genetic molecular test was positive in
255 (83.6) patients with PDB, and 143 (49.0%) of healthy controls
(p b 0.0001, OR = 5.3 [3.6; 7.8]), using the same cut-off point than
above cited. This genetic algorithm had a sensitivity of 83.6%, a speciﬁcity
of 51.0%, a PPV of 64.1% and a NPV of 74.9%. Positive and negative likeli-
hood ratios were at 1.7 and 0.3, respectively (Table 2). In the subgroup
of PDB patients with a monostotic disease, this genetic algorithm had a
sensitivity of 81.75% [73.88; 88.06] and a speciﬁcity of 51.03% [45.14;
56.90]. Second, if DNA and serum samples are available, a molecular test
integrating both genetic and biochemical markers and relying on a two
steps algorithm could be used: ﬁrst a screen in the SQSTM1 gene should
be performed to search for disease-causing germinal mutations, and if
negative, the combined score based on the logistic model integrating
both genetic and biochemical markers should be calculated (Fig. 2B). In
the subgroup of individuals for which both DNA and serum samples
were available in our populations (49 patients with PDB and 150
healthy controls), this genetic and biochemical algorithm was present
in 46 (93.9%) patients with PDB and 69 (46.0%) healthy individuals
(p b 0.0001, OR = 18.0 [5.4; 60.4]), using the same cut-off point than
above cited. In this subgroup, this genetic and biochemical algorithm
had a sensitivity of 93.9%, a speciﬁcity of 54.0%, positive and negative
likelihood ratios of 2.0 and 0.1, and a PPV and NPV of 40.0% and 96.4%,
respectively (Table 2). In the subgroup of patients with a monostotic
disease, this genetic and biochemical algorithm had a sensitivity of
100.00% [80.49; 100.00] and a speciﬁcity of 54.00% [45.68; 62.16].
4. Discussion
In patientswith PDB non-carrier of a SQSTM1mutation, a combination
ofﬁve geneticmarkers, consisting in rs499345 (EPS8L3/CSF-1), rs5742915
(PML), rs2458413 (TM7SF4), rs3018362 (RPL17P14) and rs2234968
(OPTN), adjusted for sex, gave rise to an AUC of 0.731 [0.688; 0.773],
and yielding to a sensitivity of 81.5% and a speciﬁcity of 51.0%, using a
cut-off point of 0.33 for the genetic score. This genetic combination rely-
ing on SNPs identiﬁed in GWAS and replicated in the French–
Canadian population [2,4,22], allowed the correct classiﬁcation of 81.5%
of patientswith PDB in our cohorts, non-carriers of any SQSTM1mutation,
and in 77.8% of patients with PDB coming from the multiethnic popula-
tion of New York city area, using a cut-off point of 0.33 for the genetic
score. In addition, a combination of bone biomarkers, including calcium
and P1NP, and adjusted for sex, had an AUC of 0.822 [0.726; 0.918], and
a sensitivity and a speciﬁcity of 81.5% and 48.7%, respectively. This bone
biomarker combination identiﬁed correctly 81.5% of patients with PDB
in our French and French–Canadian populations, all non-carriers of a
Fig. 2.Molecular tests proposed for the detection of PDBdeveloped in this study. A) The genetic algorithm reliesﬁrst on a screen in the SQSTM1 gene to search for disease-causing germinal
mutations. If negative, the genetic combination developed in this study should be tested. B) The genetic and biochemical algorithm relies ﬁrst on a screen in the SQSTM1 gene to search for
disease-causing germinal mutations. If negative, the combination integrating both genetic and biochemical markers developed in this study should be tested.
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score. Then, the combination of both genetic and biochemical markers
adjusted for sex increased the AUC to 0.892 [0.833; 0.951] and, using a
cut-off point of 0.05 for the combined score, this combination identiﬁed
correctly 23 patients (88.5%) with PDB. In order to cover the monogenic
component of PDB (with the presence of germinal SQSTM1mutations)
and the multifactorial aspect of the disease, we proposed two molecular
tests relying on a two steps algorithm. The genetic algorithm identiﬁed
255 (83.6%) of patients with PDB, and had a sensitivity of 83.6% and a
speciﬁcity of 51.0%. The algorithm integrating both genetic and biochem-
ical markers identiﬁed correctly 46 (93.9%) patients with PDB, and had a
sensitivity of 93.9% and a speciﬁcity of 54.0%.
Currently, the only genetic test available in PDB in some countries is
the screening for germinal SQSTM1mutations in exons 7 and 8. However,
only 15.4% of patients with PDB were carriers of a germinal SQSTM1
mutation in our population. Using a cut-off point of 0.33, the ﬁve genetic
markers combination developed in this study had a greater sensitivity
than the SQSTM1 screen for germinalmutations, suggesting that a combi-
nation of genetic markers, evenwith a small effect size, may be useful for
the detection of PDB. The AUC of the bone biomarkers combination was
higher than for the genetic markers combination. However, bone
biomarkers may have a much greater inter-individual variability, in
particular in the general population. But, combining calcium and P1NP
resulted in a greater AUC (0.822) than total ALP alone (0.739), which is
the most sensitive bone biomarker currently available to assess PDB
activity in the clinical practice. This bone biomarkers combination also
had a higher AUC than P1NP alone (0.721), which is the gold standard
to asses bone remodeling activity in PDB, but not yet available in the
clinical practice [29].
In the literature, total sALPwas reported to have a sensitivity varying
between 69% and 100% for the detection of PDB in some studies [1].
However, total sALP levels may be within the normal range, especially
in patients with a monostotic or a metabolically inactive disease, and
this should not exclude a diagnosis of PDB ([25]). Whole-body bone
scan is the most sensitive tool to detect the disease, identifying
97–98% of pagetic lesions, and bone X-rays have a sensitivity around
85–91% [18]. Imaging tests are currently the best tools for the positive
diagnosis of PDB, but remain expensive and more invasive for patients,
although they are deﬁnitely required for the positive clinical diagnosis
of PDB, according to the recent guidelines [29]. Considering the inva-
siveness and the cost of imaging methods, a molecular test relying ongenetic and bone biomarkers through a single peripheral blood sample
might represent a valuable clinical option for PDB screening. One of the
two bone biomarkers is already available in the clinical practice, at a
relatively low cost. P1NP will probably be available for clinicians in the
future, as it is the most sensitive marker for bone formation, already
cited in the American recommendations from Endocrine Society for
PDB management [29]. Although genotyping of genetic markers may
seem somehow expensive, the molecular tests proposed in this study
could represent an interesting approach from an economic point of
view to screen individuals who need to be investigated with bone
scan or not. Then, these molecular tests may avoid systematic bone
scans in all patients likely to receive a bone anabolic agent prescription,
which may be a cost-effective approach in a medium to long-term
period.
To the best of our knowledge, there is no other study in PDB that
combines genetic and bone biomarkers to detect PDB. Recently, Albagha
et al. reported thatmutations in the SQSTM1 gene, combinedwith seven
SNPs associated with PDB in the GWAS, could act in an additivemanner
to predict the extent and severity of the disease, based on a severity
score developed by the authors and not yet validated. This combination
had a sensitivity of 70% and a speciﬁcity of 55% to predict the severity of
PDB [3].
The molecular test integrating the screening for germinal SQSTM1
mutation, followed by the test for the genetic and biochemical markers
combination, had the greatest intrinsic and extrinsic characteristics in
our populations, identifying correctly 93.9% of PDB-affected patients.
However, given the small sample of individuals available to test this
algorithm, the genetic algorithm seemed more appropriate for the
detection of PDB in our population, with a more representative number
of individuals available for genetic analysis. But, these results suggest
that the screening of genetic and biochemical markers should be a
valuable tool to improve the positive diagnosis of PDB, considering the
lack of sensitivity of total sALP and the clinical necessity to accurately
rule out PDB before using bone anabolic agents. The presence of the
genetic combination with a similar frequency in a multiethnic popula-
tion from New York City, as well as in the French and French–Canadian
populations, may suggest that it could be used in different countries,
where PDB is observed. Regarding bone resorption biomarkers,
although C-telopeptide serum levels were signiﬁcantly higher in
patients than in controls in univariate analyses, this biomarker was
not retained in multivariate analyses. A recent meta-analysis
220 S. Guay-Bélanger et al. / Bone 84 (2016) 213–221demonstrated that the urinary N-terminal telopeptide (uNTX) is the
bone resorption biomarker with the highest sensitivity to detect PDB
[1], but this biomarker requires a urinary sample either second AM
urine or 24-hour urine collection which limits its feasibility in the clini-
cal practice. Regarding the sclerostin levels, increased serum sclerostin
levels in comparison to controls were previously reported in the
literature [31]. Surprisingly, we found that PDB patients had statistically
signiﬁcant decreased serum sclerostin levels in comparison to controls
in univariate analyses. These results could be explained by the fact
that most patients included in this study were previously treated,
which could give rise to a lower disease activity. Our study has some
limitations. First, the speciﬁcity close to 50% for the molecular tests
developed in this study could somehow seem low, especially in compar-
ison with the speciﬁcity of imaging techniques. However, since imaging
tests will be performed in all individuals who will be positive for these
tests to conﬁrm or rule out the PDB diagnosis, the limited speciﬁcity is
acceptable in this case. In fact, a better sensitivity was prioritized in
order to identify the highest number of predisposed individuals. Also,
the small number of samples available for bone biomarkers measure-
ment may have biased the intrinsic and extrinsic characteristics of the
genetic and biochemical combined algorithm in our study. It should
also be of paramount importance to replicate themolecular tests devel-
oped in this study in amuch larger cohort with genetic and biochemical
samples available for patients with PDB and healthy controls. Second,
the genetic combination was detected in 49.0% of healthy controls and
the genetic and bone biomarkers combination was detected in 46.0%
of healthy controls, whichmay represent a high number of false positive
for whomwhole body bone scan followed by centered X-rays would be
required to conﬁrm or inﬁrm the PDB diagnosis. Another validation
study should be represented by the trial of these molecular tests in a
large cohort of healthy individuals aged 60 years old or more, likely to
receive a prescription of a bone anabolic agent for osteoporosis treat-
ment, to validate their accuracy and reliability to identify individuals
with asymptomatic PDB. Of note, some of the patients with PDB from
our cohorts have received bisphosphonates before serum sampling
which may has decreased the sensitivity of some bone biomarkers,
but may be more close to the clinical reality, where patients usually
receive bisphosphonate therapy before bone anabolic agents. If replicat-
ed and validated with the ACCE (analytic validity; clinical validity;
clinical utility; ethical, legal and social implications) criteria ([16]),
these molecular tests might become a companion test before initiating
bone anabolic agents to improve safety.
In conclusion, we have developed twomolecular tests: a pure genetic
molecular test, integrating ﬁrst a screen for SQSTM1 germinal mutations,
followed in non-carriers, by a geneticmarkers combination, and a genetic
and biochemicalmolecular test, integrating a screen for SQSTM1 germinal
mutations, followed in non-carriers, by a genetic and biochemical
markers combination. These two molecular tests predicted the PDB
phenotype better than total ALP or P1NP alone, considered as gold
standards, in our populations. Further studies are now warranted in
other populations to improve these molecular tests for a possible future
use in the clinical practice.
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